Aripiprazole (Abilify Maintena)

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Schizophrenia, Bipolar Disorder

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (1)
EU
  • Maintenance treatment of schizophrenia in adult patients stabilised with oral aripiprazole.
Product first approved 2013EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (10)
Bipolar Disorder
NCT01710709 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2012-11 – 2016-12 · Bipolar I
What this study did
Schizophrenia
NCT01959035 · H. Lundbeck A/S
2013-10 – 2015-03 · Schizophrenia
What this study did
NCT01795547 · H. Lundbeck A/S
2013-02 – 2014-09 · Schizophrenia
What this study did
NCT01683058 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2013-01 – 2014-02 · Schizophrenia
What this study did
NCT00731549 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2008-12 – 2013-11 · Schizophrenia
What this study did
Phase 1 (7)
Schizophrenia
NCT03287505 · Otsuka Beijing Research Institute
2017-06-23 – 2019-11-08 · Schizophrenia
What this study did
NCT03285503 · Otsuka Beijing Research Institute
2018-08-17 – 2019-10-14 · Schizophrenia
What this study did
NCT01909466 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2013-07 – 2014-04 · Schizophrenia, Mental Disorder, Nervous System Diseases
What this study did
NCT01646827 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2012-05 – 2013-04 · Schizophrenia
What this study did
NCT01552772 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2012-01 – 2012-04 · Schizophrenia
What this study did
NCT01870999 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2007-11 – 2008-10 · Schizophrenia
What this study did
Phase 4 (11)
Bipolar Disorder
NCT03408873 · Martha Sajatovic
2018-04-01 – 2020-05-06 · Bipolar Disorder, Medication Adherence, Medication Non Adherence
What this study did
Schizophrenia
NCT03376763 · Korea Otsuka Pharmaceutical Co., Ltd.
2017-11-21 – 2021-11-19 · Schizophrenia, Antipsychotics, Long-Acting Injection, LAI, Aripiprazole
What this study did
NCT03839251 · Chonbuk National University Hospital
2018-06-01 – 2020-09-30 · Schizophrenia
What this study did
NCT02146547 · UMC Utrecht
2015-02 – 2020-08-26 · Schizophrenia
What this study did
NCT02237417 · University of Utah
2014-09-01 – 2020-07-30 · Schizophrenia
What this study did
NCT02360319 · Vanguard Research Group
2014-12-11 – 2019-03-31 · Schizophrenia
What this study did
NCT02697045 · Abdi İbrahim Otsuka
2017-01-04 – 2018-03-31 · Schizophrenia
What this study did
NCT02282085 · Matt Byerly
2014-12 – 2017-12 · Schizophrenia
What this study did
NCT01047215 · Taichung Veterans General Hospital
2009-08 – 2010-06 · Schizophrenia, Bipolar
What this study did
NCT00325689 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2006-07 – 2007-10 · Schizophrenia, Schizoaffective Disorder
What this study did
Other / comorbidity
NCT02472652 · Gazda, Thomas D., M.D., PC
2015-06 – 2017-03-01 · Sexual Dysfunction
What this study did
Early phase / not applicable (3)
Schizophrenia
NCT02926976 · Shanghai Mental Health Center
2016-11 – 2019-09 · Schizophrenia
What this study did
NCT02007928 · Centre Hospitalier Universitaire de Nice
2013-04 – 2017-07 · Dissociative Disorders, Schizophrenia
What this study did
NCT02717130 · Florida Atlantic University
2016-06-08 – 2017-05-25 · Schizophrenia
What this study did
Used as active comparator (1)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 1 (1)
Schizophrenia
NCT05402111 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2022-06-13 – 2023-09-27 · Schizophrenia
What this study did
Appears in other studies (2)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 4 (1)
Schizophrenia
NCT02040883 · Qingyun Yin
2014-02 – 2014-12 · Schizophrenia
What this study did
Early phase / not applicable (1)
Schizophrenia
NCT03019887 · Juntendo University
2011-04 – 2017-01 · Schizophrenia Relapse
What this study did

Competitive landscape

5 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Bipolar Disorder: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Aripiprazole (Abilify Maintena): this drugApprovedSmall moleculeDopamine D2/D3 and serotonin 5-HT1A receptor, Dopamine D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D2 receptor (partial agonist)not yet gradedNo reviewed efficacy summary in this indication
Aripiprazole (Abilify)ApprovedSmall moleculeDopamine D2/D3 and serotonin 5-HT1A receptornot yet gradedNo reviewed efficacy summary in this indication
AsenapineApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Cariprazine (Vraylar)ApprovedSmall moleculeDopamine D3/D2 receptor (partial agonist)not yet gradedNo reviewed efficacy summary in this indication
Divalproex Sodium (Depakote ER)ApprovedSmall moleculeGABAergic neurotransmissionnot yet gradedNo reviewed efficacy summary in this indication
Divalproex Sodium (Depakote)ApprovedSmall moleculeGABAergic neurotransmissionPartial signalFeatured results are non-efficacy only in this race
Iloperidone (Fanapt)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
LamotrigineApprovedSmall moleculeVoltage-gated sodium channelnot yet gradedNo reviewed efficacy summary in this indication
Milsaperidone (VHX-896)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Weak signalNo reviewed efficacy summary in this indication
Olanzapine (Zyprexa)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Olanzapine / Samidorphan (Lybalvi)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist); mu-opioid receptor (antagonist)Reliable signalNo reviewed efficacy summary in this indication
Quetiapine (Seroquel XR)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Quetiapine (Seroquel)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Risperidone (Risperdal Consta)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Risperidone (Risperdal)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Risperidone (Rykindo)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Risperidone (Uzedy)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
ZiprasidoneApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Dexmedetomidine (Igalmi)Phase 3Small moleculeAlpha-2 adrenergic receptor (agonist)Reliable signalNo reviewed efficacy summary in this indication
Loxapine (Adasuve)Phase 3Small moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Partial signalNo reviewed efficacy summary in this indication
Xanomeline / Trospium Chloride (Cobenfy)Phase 3Small moleculeMuscarinic M1/M4 receptor (agonist/antagonist combination)not yet gradedNo reviewed efficacy summary in this indication
ALTO-100Phase 2Small moleculeFirst-in-class oral small molecule neural plasticity enhancernot yet gradedNo reviewed efficacy summary in this indication
BrenipatidePhase 2PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
ElunetiromPhase 2Small moleculeThyroid hormone receptor-betanot yet gradedNo reviewed efficacy summary in this indication
IcalcaprantPhase 2Small moleculeKappa-opioid receptor (inhibitor)not yet gradedNo reviewed efficacy summary in this indication
Lithium Salicylate / L-Proline (AL001)Phase 1/2Small molecule—not yet gradedNo reviewed efficacy summary in this indication
ABBV-1042
Phase 1(overall)
Small moleculeMuscarinic M4 receptornot yet gradedNo reviewed efficacy summary in this indication
Aripiprazole (Abilify MyCite)DiscontinuedCombinationDopamine D2 and serotonin 5-HT1A receptors (partial agonist); serotonin 5-HT2A receptor (antagonist)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.